BASIC SCIENCE (SC)
- NEUROANATOMY FOR THE MS CLINICIAN: INSIGHTS AND CLINICAL PEARLS
Aliza Ben-Zacharia, PhD, DNP, ANP-BC, FAAN Stephen Krieger, MD, FAAN- Introduction and Clinical Pearls
Aliza Ben-Zacharia, PhD, DNP, ANP-BC, FAAN - The Brainstem and Cranial Nerves
Stephen Krieger, MD, FAAN - The Spinal Cord
Aliza Ben-Zacharia, PhD, DNP, ANP-BC, FAAN
- CASES IN NEUROMYELITIS OPTICA SPECTRUM DISORDER AND MOG ANTIBODY-ASSOCIATED DISEASE
Eoin P. Flanagan, MBBCh, Chair - BASIC AND ADVANCED IMMUNOLOGY FOR THE NON-IMMUNOLOGISTC
Scott D. Newsome, DO, MSCS, FAAN, FANA, Chair- Welcome and Introduction
Scott D. Newsome, DO, MSCS, FAAN, FANA - How Does the Immune System Protect Us?
Lisa Fox, PA-C, MPAS - The Immune System Goes Rogue in Multiple Sclerosis
Jennifer Orthmann-Murphy, MD, PhD - Understanding immune Responses of Brain Resident Cells Informs Next Generation Therapies for Progressive MS
Peter Calabresi, MD, FAAN, FANA
- DISEASE MANAGEMENT PLATFORMS
- DMX01 » Web: A Pilot Study of Wearables for Bladder Monitoring in People with Multiple Sclerosis
Valerie J. Block, PT, DPTSc - DMX02 » Disease Activity in People with Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder Exposed to Immune Checkpoint Inhibitors: A Multi-Institutional Study
Alexander J. Gill, MD, PhD - DMX03 » Comparison between a Remote Versus Clinic-Based Exercise Intervention for People with Multiple Sclerosis Residing in the Deep South: An Enhancement Non-Inferiority Trial
Salma M. Aly, MD, MPH - DMX04 » Symptom Comparison after Infections Among People with MS
Amber Salter, PhD - DMX05 » Outcomes from a Women’s Health Initiative at the Vanderbilt Multiple Sclerosis Center
Stephanie Taylor, MD - DMX06 » Characterizing Neuro-Qol in Latinx People with Multiple Sclerosis during the COVID-19 Pandemic
Carrie M. Hersh, DO, MSc, FAAN
- DISEASE MODIFYING THERAPIES PLATFORMS
- DMT01 » Effect of Cladribine Tablets on Markers of Disease Progression, Axonal Loss and Oligoclonal Bands in Patients with Relapsing Multiple Sclerosis: Results from MAGNIFY-MS
Nicola De Stefano, MD, PhD - DMT02 » Ocrelizumab Dose Selection for Treatment of Pediatric Relapsing- Remitting Multiple Sclerosis: Pharmacokinetic, Safety, and Efficacy Results from OPERETTA 1
Teri Schreiner, MD, MPH - DMT03 » Safety and Efficacy of Frexalimab in Relapsing Multiple Sclerosis: 48- Week Results from the Phase 2 Open-Label Extension
Yang Mao-Draayer, MD, PhD - DMT04 » Relapse-Associated Worsening and Progression-Independent Relapse Activity in Ozanimod-Treated Participants with Relapsing Multiple Sclerosis from the RADIANCE and DAYBREAK Trials
Jeffrey A. Cohen, MD - DMT05 » Pregnancy and Infant Outcomes in Females Receiving Ocrelizumab for the Treatment of Multiple Sclerosis: Analysis of over 3,000 Pregnancies to Date
Riley Bove, MD - DMT06 » Ocrelizumab Administered Subcutaneously: Results from the Clinical Development Program
Scott D. Newsome, DO, MSCS
- MS MIMICS: DIFFERENTIAL DIAGNOSIS IN PEDIATRIC AND LATE ONSET POPULATIONS
Le Hanh Hua, MD, Chair - WHITAKER LECTURE
UPDATES ON CELLULAR THERAPIES FOR MULTIPLE SCLEROSIS (Click here for the slides)
Click here to watch the video
Jeffrey A. Cohen, MD - WHITAKER TRACK INVITED LECTURES- THE UNSEEN AND SEEN SYMPTOMS OF MS – DIFFERENT PERSPECTIVES
Ahmed Zayed Obeidat, MD, PhD, Chair - THE OPTIC NERVE IN MS DIAGNOSTIC CRITERIA
Wallace Brownlee, MBChB, PhD, FRACP, Chair- Introduction
Wallace Brownlee, MBChB, PhD, FRACP - Diagnosis and Differential Diagnosis of Optic Neuritis
Steven Galetta, MD - Evaluation of the Optic Nerve with MRI
Jiwon Oh, MD, PhD, FRCPC - Evaluation of the Optic Nerve with OCT and Visual Evoked Potentials
Fiona Costello, MD, FRCP - Integrating the Optic Nerve into MS Diagnostic Criteria
Wallace Brownlee, MBChB, PhD, FRACP - Clinical Cases for Discussion
Panel
- MICROGLIA AND ASTROCYTES IN MS: BIOLOGY, PET IMAGING AND THERAPEUTICS
Wee Yong, PhD, FCAHS, FRSC, Chair - MYELITIS AND MYELOPATHIES: RECOGNIZING INFLAMMATORY, INFECTIOUS AND NON-INFLAMMATORY MYELOPATHIES
Paula Barreras, MD, Chair - WHITAKER PLATFORM SESSION
Ahmed Zayed Obeidat, MD, PhD, Chair- Introduction
Ahmed Zayed Obeidat, MD, PhD - CSF Perturbation of Human Primary Astrocytes to Model the Link between CSF Pathogenicity and Neurodegeneration in Multiple Sclerosis
Bianca Trombetta, BA - Identifying Biophysical Markers That Predict Perceived Walking, Balance and Physical Quality of Life in People with Multiple Sclerosis
Katrina Williams, MD - Pre-Clinical Testing of Novel Small Molecules Inhibit Neurodegeneration – Implications for the Pathogenesis and Treatment of MS
Cole Libner, PhD - Healthcare-Related Social Determinants of Health Are Associated with Regional Cortical Thickness and Accelerated Brain Aging in Persons with Multiple Sclerosis
Cristina A.F. Román, PhD - Relationship between Immune Cell Bioenergetics and Disease Status in People with Multiple Sclerosis: A Pilot Study
Kathryn Kern, PhD, MS - Metabolic Alterations in Multiple Sclerosis and Correlation with Disease Severity
Rezvan Noroozi, PhD - Closing Remarks
Ahmed Zayed Obeidat, MD, PhD
- THE EXPANDING ROLE OF FLUID BIOMARKERS IN THE MANAGEMENT OF MS
Mark Freedman, HBSc, MSc, MD, CSPQ, FAAN, FRCPC, Chair - CONTROVERSY OF USING ADAPTATIVE DOSING OR DISCONTINUATION OF ANTI-CD20S IN TREATING MS
Carolina Ionete, MD, PhD Chair- Opening Remarks
Carolina Ionete, MD, PhD - Epidemiology of Extended Interval Dosing of Ocrelizumab
Ellen Mowry, MD, MCR, FAAN, FANA - Different Anti-CD20 mAbs and Evidence for Clinical Trials and Long-term Use in Treating MS
Carolina Ionete, MD, PhD - Evolving Rationale for Anti-CD20 Discontinuation
Amit Bar-Or, MD, FRCPC - Should MS Therapies Ever Be Discontinued?
Roberto Bomprezzi, MD - Closing Remarks
Carolina Ionete, MD, PhD
- ADVOCATING FOR DAY PROGRAMS AS PART OF COMPREHENSIVE CARE FOR MS
Brian Hutchinson, PT, MSCS, Chair- Introduction to MS Day Programs
Brian Hutchinson, PT, MSCS - History and Evolution of MS Day Programs
Randall T. Schapiro, MD, FAAN - The Loneliness & Isolation Epidemic: A Needs Assessment for MS Day Programs
Tiffany Malone, MSW, MSCS - Healing Effects of Social Connection & Community
Rachael Stacom, ANP-BC, MSN, MSCN - Coming to Consensus of MS Day Programs
Brian Hutchinson, PT, MSCS
- HOW THE GUT-BRAIN AXIS AFFECTS MS: DIET AND MICROBIOME
Ari Waisman, PhD, Chair
MENTAL HEALTH (MH)
- UNDERSTANDING FATIGUE AND ITS CLINICAL MANAGEMENT
John DeLuca, PhD, ABPP, FACRM, FAPA, FAPS, FNAN, Chair - TREATING COGNITIVE IMPAIRMENT IN MS: WHAT WORKS AND WHAT DOESN’T
John DeLuca, PhD, ABPP, FACRM, FAPA, FAPS, FNAN, Chair - PSYCHOSOCIAL PLATFORMS
- CONVEYING INFORMATION: HOW YOU SAY IT MATTERS
Angela Lesley Baufeldt, DClinPsy, Chair - ASSESSMENT AND TREATMENT OF SEXUAL DYSFUNCTION IN ONE VISIT
Frederick W. Foley, PhD, Chair - WHITAKER TRACK INVITED LECTURES- THE UNSEEN AND SEEN SYMPTOMS OF MS – DIFFERENT PERSPECTIVES
Ahmed Zayed Obeidat, MD, PhD, Chair - HOLISTIC FRAMEWORKS FOR UNDERSTANDING COGNITIVE AND PSYCHOLOGICAL SYMPTOMS IN PEOPLE WITH MULTIPLE SCLEROSIS
Terry Lee-Wilk, PhD, Chair- Part I: Review of Holistic Frameworks for Understanding Cognitive and Psychological Symptoms in People with MS
Terry Lee-Wilk, PhD; Moira Dux, PhD; Jessica Dalrymple, PhD - Part II: Application of Holistic Frameworks Managing Cognitive and Psychological Symptoms in People with MS
Terry Lee-Wilk, PhD; Moira Dux, PhD; Jessica Dalrymple, PhD
MS MANAGEMENT (MG)
- THE ERA OF TOO MANY CHOICES: STARTING AND SWITCHING MS DISEASE MODIFYING THERAPIES
Scott D. Newsome, DO, MSCS, FAAN, FANA, Chair- Welcome and Introduction
Scott D. Newsome, DO, MSCS, FAAN, FANA - Treatment Approaches and Considerations in MS
Scott D. Newsome, DO, MSCS, FAAN, FANA - Decision Making Process Around What DMT to Start
Gabrielle Macaron, MD - Decision Making Process Around Switching DMTs in MS
Jiwon Oh, MD, PhD, FRCPC - Panel Roundtable-Case Presentations
Panel
- APPLICATION OF HISTORY & NEUROLOGIC EXAMINATION FOR ACCURATE EXPANDED DISABILITY STATUS SCORE (EDSS) ASSESSMENT
Michael Yeung, MD, FRCPC Jodie Roberts, MD, MSc, FRCPC Co-Chairs- Introduction – Overview of the EDSS – Benefits, Drawbacks, and Historical Significance
Jodie Roberts, MD, MSc, FRCPC - Scoring Kurtzke Functional Systems and Calculating the EDSS
Michael Yeung, MD, FRCPC - Additional Practice Cases
Michael Yeung, MD, FRCPC - Other Common MS Outcome Measures – MSFC & SDMT
Jodie Roberts, MD, MSc, FRCPC
- DILEMMAS IN LONG-TERM DMT MANAGEMENT
Colleen Harris, MN, NP, MSCN, MSCS, Chair- Introduction
Colleen Harris, MN, NP, MSCN, MSCS - Selection and Sequencing Challenges
Jennifer Chester, APRN, MSCN, AQH - Ongoing Monitoring and When to Stop Therapy
Colleen Harris, MN, NP, MSCN, MSCS - Motivating Our Patients with Long Term Adherence
Kathleen Fuchs, PhD, ABPP - Case Studies
Panel
- MRI INTERNATIONAL GUIDELINES IN CLINICAL PRACTICE: CURRENT AND UP-AND-COMING APPROACHES
David K.B. Li, MD; Anthony Traboulsee, MD Co-Chairs- Welcome and Introductions
Anthony Traboulsee, MD - MRI and the Diagnosis and Misdiagnosis of MS
Jiwon Oh, MD, PhD, FRCPC - MS Lesions and Lesion Red Flags
Mike P. Wattjes, MD, PhD - Up-and-coming MRI Biomarkers
Mike P. Wattjes, MD, PhD - MRI in Follow-up for Treatment Effectiveness and Safety
Anthony Traboulsee, MD - Standardized MRI Protocol for MS
David K.B. Li, MD
- THE LIFE OF A WOMAN WITH MS: A CASE-BASED APPROACH FROM PREGNANCY AND BEYOND
Rohini Samudralwar, MD, Chair- Introduction: Following Different Scenarios in one Woman’s Journey with MS
Rohini Samudralwar, MD - Present Patient Background
Rohini Samudralwar, MD - Time of Diagnosis: Pre-pregnancy – Continuing DMT During Pregnancy, IVF, and Nursing
Dina Jacobs, MD - Present Patient Background
Rohini Samudralwar, MD - Time of Diagnosis: During Pregnancy – Confirmation of MS, Starting DMT, Managing Relapses
Riley Bove, MD - Present Patient Background
Rohini Samudralwar, MD - Time of Diagnosis: Post Pregnancy – Nursing, Relapses while Nursing, Planning for More Children
Maria K. Houtchens, MD, MMs
- OPTIMIZING CARE IN MS
Jodie Haselkorn, MD, MPH, Chair
Organized by the VA MS Centers of Excellence - COMORBIDITY MANAGEMENT AMONG PEOPLE WITH MULTIPLE SCLEROSIS: THE ROLE OF REGISTERED DIETITIAN NUTRITIONISTS
Tyler J. Titcomb, PhD, RDN, Chair - PRESIDENTIAL LECTURE
MULTIPLE SCLEROSIS- 30 YEARS ON FROM FIRST THERAPY: WHAT HAVE WE LEARNED (Click here for the slides)
Click here to watch the video
Fred D. Lublin, MD - VIDEO: FUNDAMENTALS OF MS CARE – PART 1 (Valid for credit through September 1, 2026)
Constance B. Easterling, RN, MSN, APRN, MSCN, Moderator- Welcome and Overview of Program
Constance B. Easterling, RN, MSN, APRN, MSCN - The Natural History of MS (Epidemiology, Immunology, Pathophysiology)
Bruce Cohen, MD - Making the Diagnosis (Disease Mimics, Use of Paraclinical Tools)
Derrick Robertson, MD - Pediatric MS Management and Transition to Adult Care
Yolanda Wheeler, PhD, CRNP, CPNP-AC, MSCN - Use and Effectiveness of Marijuana in MS: Research Update
Anthony Feinstein, MD, PhD, FRCPC
- CURRENT TOPICS AND TRENDS IN MS REHAB – PART 1
THE MULTIDISCIPLINARY HOLISTIC MANAGEMENT OF MS SYMPTOMS TO IMPROVE QUALITY OF LIFE
Patricia Bobryk, MHS, PT, MSCS, ATP, Moderator; Susan Linder, DPT, PhD, Chair - BACK TO THE BASICS: AN INTERDISCIPLINARY APPROACH TO MANAGEMENT OF BLADDER AND BOWEL SYMPTOMS
Marie Namey, APRN, MSCN, Chair- Introduction and Focus of Symposia
Marie Namey, APRN, MSCN - The Bladder in MS, Diagnosis and Management
Philip J. Aliotta, MD, MSHA, FACS - Strategies for Assessment and Management of MS Bowel Symptoms
Marie Namey, APRN, MSCN - Optimizing Bladder and Bowel Function from a Rehabilitation Perspective
Cameron Pikula, PT, DPT - Case Studies, Discussion and Questions
Panel
- AGING IN MS
Jennifer Graves, MD, PhD, MAS, Chair - BACK TO THE FUTURE: ASK THE PHARMACIST
Jenelle H. Montgomery, PharmD, BCACP, CPP, Chair- Welcome, Introduction and Overview
Jenelle H. Montgomery, PharmD, BCACP, CPP - Academic Institution
Megan Schneider, PharmD - Private Practice
Julie Kidd, PharmD, MPH, BCPs - Outcomes Management: Benefits of a Pharmacist in the MS Clinic
Jenelle H. Montgomery, PharmD, BCACP, CPP - Pharmacy Technician Support in an MS Center
Shanay Saunders, CPHT
- DISEASE MANAGEMENT PLATFORMS
- DMX01 » Web: A Pilot Study of Wearables for Bladder Monitoring in People with Multiple Sclerosis
Valerie J. Block, PT, DPTSc - DMX02 » Disease Activity in People with Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder Exposed to Immune Checkpoint Inhibitors: A Multi-Institutional Study
Alexander J. Gill, MD, PhD - DMX03 » Comparison between a Remote Versus Clinic-Based Exercise Intervention for People with Multiple Sclerosis Residing in the Deep South: An Enhancement Non-Inferiority Trial
Salma M. Aly, MD, MPH - DMX04 » Symptom Comparison after Infections Among People with MS
Amber Salter, PhD - DMX05 » Outcomes from a Women’s Health Initiative at the Vanderbilt Multiple Sclerosis Center
Stephanie Taylor, MD - DMX06 » Characterizing Neuro-Qol in Latinx People with Multiple Sclerosis during the COVID-19 Pandemic
Carrie M. Hersh, DO, MSc, FAAN
- DISEASE MODIFYING THERAPIES PLATFORMS SC
- DMT01 » Effect of Cladribine Tablets on Markers of Disease Progression, Axonal Loss and Oligoclonal Bands in Patients with Relapsing Multiple Sclerosis: Results from MAGNIFY-MS
Nicola De Stefano, MD, PhD - DMT02 » Ocrelizumab Dose Selection for Treatment of Pediatric Relapsing- Remitting Multiple Sclerosis: Pharmacokinetic, Safety, and Efficacy Results from OPERETTA 1
Teri Schreiner, MD, MPH - DMT03 » Safety and Efficacy of Frexalimab in Relapsing Multiple Sclerosis: 48- Week Results from the Phase 2 Open-Label Extension
Yang Mao-Draayer, MD, PhD - DMT04 » Relapse-Associated Worsening and Progression-Independent Relapse Activity in Ozanimod-Treated Participants with Relapsing Multiple Sclerosis from the RADIANCE and DAYBREAK Trials
Jeffrey A. Cohen, MD - DMT05 » Pregnancy and Infant Outcomes in Females Receiving Ocrelizumab for the Treatment of Multiple Sclerosis: Analysis of over 3,000 Pregnancies to Date
Riley Bove, MD - DMT06 » Ocrelizumab Administered Subcutaneously: Results from the Clinical Development Program
Scott D. Newsome, DO, MSCS
- NEUROIMAGING PLATFORMS
- IMG01 » A 2-Stage Model of Heterogenous Treatment Effects for Brain Atrophy in Multiple Sclerosis Utilizing the MS Paths Research Network
Carrie M. Hersh, DO, MSc, FAAN - IMG02 » Relationship between Serum 24-Hydroxycholesterol and Brain Water Content, Myelin Water Fraction, and T1 Relaxation in Different Stages of MS
Noah Marini, BScN - IMG03 » How to Use Neuro Innovation in Clinical Practice Exploring Radiologically Isolated Syndrome
Mikael Cohen, MD, PhD - IMG04 » Identification of a Distinct Microglial Inflammation Pattern in the Subcortex of MS Patients Using Principal Component Analysis Applied to [11C]PBR28 PET Images
Risavarshni Thevakumaran, BEng, MSc - IMG05 » Performance Evaluation of Neuroquant MS 4.1 for White Matter Lesion Segmentation in Multiple Sclerosis
Saif Baig, MD - IMG06 » Assessing Central Vein Sign Visibility across Various Anisotropic MRI Resolutions for Multiple Sclerosis Diagnosis
Samuel W. Remedios, MSE
- VIDEO: FUNDAMENTALS OF MS CARE – PART 2 (Valid for credit through September 1, 2026)
Constance B. Easterling, RN, MSN, APRN, MSCN, Moderator- Welcome and Overview
Constance B. Easterling, RN, MSN, APRN, MSCN - Primary Progressive MS: Diagnosis, Clinical Course, and Management
Patricia K. Coyle, MD, FAAN, FANA - MRI Mimics in the Diagnosis of MS
David Li, MD - Women’s Issues in MS
Anna Shah, MD - Shared Decision Making in Treatment Selection
Patricia Pagnotta, APRN, MSN, CNRN, MSCN
- VIDEO FUNDAMENTALS OF MS CARE – PART 3
(Valid for credit through September 1, 2026)
Beverly Layton, RN, BSN, MSCN, Moderator- Welcome and Overview
Beverly Layton, RN, BSN, MSCN - Approaches to Disease Modifying Therapy in RRMS
John Rinker II, MD - Behind the Scenes of Therapy and Changing Disease Course
Crystal Wright, AGPCNP-BC, MSCN - Branded, Generic and Biosimiliar Options- The Pharmacist Approach to Emerging Treatment Options
Erica Goff, PharmD, BCPS, MSCS - Separating Clinical Nutrition from Clickbait. Evidence-Based Nutrition Recommendations for (PwMS) People with Multiple Sclerosis
Mona Bostick, RDN, LDN, MSCS
- TREATMENT STRATEGIES IN RELAPSING MS: WHAT HAVE WE LEARNED FROM OBSERVATIONAL STUDIES AND BEYOND
Scott D. Newsome, DO, MSCS, FAAN, FANA, Chair- Welcome and Introduction
Scott D. Newsome, DO, MSCS, FAAN, FANA - Birds Eye View on Treatment Strategies
Scott D. Newsome, DO, MSCS, FAAN, FANA - Treatment Strategies in Multiple Sclerosis are Clear as a Crystal
Tirisham Gyang, MD - Treatment Strategies in Multiple Sclerosis are Clear as Mud
Ellen Mowry, MD, MCR, FAAN, FANA - Panel Roundtable-Case Presentations
Panel
- LOOKING INTO THE FUTURE: THE HOPE AND THE REALITY
MG
Patricia K. Coyle, MD, FAAN, FANA, Chair- Artificial Intelligence and Quantum Computers
Patricia K. Coyle MD, FAAN, FANA - Biomarkers
Patricia K. Coyle MD, FAAN, FANA - Novel Therapies
Patricia Melville, RN, MSN, NP-BC, MSCN - Targeting Aging
Marijean Buhse, PhD, NP-BC, MSCN, FAAN - Role of Glia
Patricia K. Coyle MD, FAAN, FANA - Patient Reported Outcomes
Marijean Buhse, PhD, NP-BC, MSCN, FAAN - Gut Microbiome
Patricia Melville, RN, MSN, NP-BC, MSCN - MS Prodrome
Patricia Melville, RN, MSN, NP-BC, MSCN
- SPECIFIC CONSIDERATIONS WITH MS THERAPIES: WHAT THE PRACTITIONER NEEDS TO KNOW
Jacquelyn Bainbridge, PharmD, FCCP, MSCS, FAES, Chair, Moderator- Welcome, Introduction and Overview
Jacquelyn Bainbridge, PharmD, FCCP, MSCS, FAES - Conversations with your MS Patients
Sara Schaefer, NP-BC, CNRN, MSCN - Neuropathic Pain, Bowel and Bladder Dysfunction
Ross Tingen, PharmD, BCPS, MSCS - Complementary and Alternative Medicine: Cannabis, Diet, etc.
Jacquelyn Bainbridge, PharmD, FCCP, MSCS, FAES - Navigating Challenging Cases: Undiagnosed, Deprescribing, DMT Hesitant Patient
Anna Shah, MD
- DONALD PATY LECTURE
PEDIATRIC MS 2024 (Click here for the slides)
Click here to watch the video
Ann Yeh, MA, MD, FRCPC, Dip ABPN - VIDEO: FUNDAMENTALS OF MS CARE – PART 4
(Valid for credit through September 1, 2026)
Beverly Layton, RN, BSN, MSCN, Moderator- Welcome and Overview
Beverly Layton, RN, BSN, MSCN - Clinic Coordination: How to Survive in this Changing Environment
Tomicka McMillion, DNP, RN, MSCN - Comorbidities and Multiple Sclerosis
Sara Schaefer, NP-BC, CNRN, MSCN - Caring for Men with Multiple Sclerosis
Jeffrey Hernandez, DNP, APRN, MSCN - Case Studies
Panel
- MS IN UNDERSERVED POPULATIONS: UNDERSTANDING NEEDS AND IMPROVING OUTCOMES
Mitzi Joi Williams, MD, FAAN, Chair - HOT TOPICS
Corey C. Ford, MD, PhD, Chair
REHABILITATION (RH)
- CURRENT TOPICS AND TRENDS IN MS REHAB – PART 1
THE MULTIDISCIPLINARY HOLISTIC MANAGEMENT OF MS SYMPTOMS TO IMPROVE QUALITY OF LIFE
Patricia Bobryk, MHS, PT, MSCS, ATP, Moderator; Susan Linder, DPT, PhD, Chair - REHABILITATION PLATFORMS
- REH01 » Free-Living Ambulatory Physical Activity and Cognitive Function in Multiple Sclerosis: The Significance of Step Rate Vs. Step Volume
Peixuan Zheng, PhD - REH02 » Project Teaams – Targeted Exercise for African-Americans with Multiple Sclerosis: Preliminary Results
Victoria A. Flores, PhD - REH03 » Intermittent Hypoxia-Induced Neuroplasticity in Persons with Multiple Sclerosis
Milap Sandhu, PT, PhD - REH04 » Relationships between Perceived Fatigue, Ambulation Fatigability, Daily Ambulatory Activity, and Energy Cost of Walking in Multiple Sclerosis: A Pilot Study
Prudence Plummer, PhD, PT - REH05 » Ambulatory Activity between Anti-CD20 Antibody Infusions in People with Multiple Sclerosis
Valerie J. Block, PT, DPTSc
- CURRENT TOPICS AND TRENDS IN MS REHAB – PART 2
PRO-MS: PROVIDER COMMUNICATION AS THE KEY FOR PROMOTING PROACTIVE REHABILITATION IN MS
Patricia Bobryk, MHS, PT, MSCS, ATP, Moderator; Marissa Barrera, PhD, MSCS, CCC-SLP; Erin Giroux, BScOT(c), MSCS Co-Chairs- Introduction of Panelists and Goals for the Session
Marissa Barrera, PhD, MSCS, CCC-SLP; Erin Giroux, BScOT(c), MSCS - Rationale for the Immediate Evaluation/Screening for PwMS at Diagnosis
Panel - Patient Preparedness & Developing Engagement for Participation in Multidisciplinary Assessment
Panel - Assessment Tools for Physical Medicine & Rehabilitation – Part 1 – Physical Therapy
Nora Fritz, PhD, PT, DPT, NCS; Randy Karim, PT, DPT, NCS, CBIS - Assessment Tools for Physical Medicine & Rehabilitation – Part 2 – Occupational Therapy
Erin Giroux, BScOT(c), MSCS; Kathleen Zackowski, PhD, OTR/L - Assessment Tools for Physical Medicine & Rehabilitation – Part 3 – Medical Speech-Language Pathology
Marissa Barrera, PhD, MSCS, CCC-SLP; Rachel Haines, MA, CCC-SLP, MSCS, CBIS - Discussion: Barriers, Roadblocks and Blockades Panel
- WHITAKER TRACK INVITED LECTURES- THE UNSEEN AND SEEN SYMPTOMS OF MS – DIFFERENT PERSPECTIVES
Ahmed Zayed Obeidat, MD, PhD, Chair - CURRENT TOPICS AND TRENDS IN MS REHAB – PART 3
BODY COMPOSITION IN MULTIPLE SCLEROSIS: STATE OF THE KNOWLEDGE FOR GUIDING RESEARCH AND CLINICAL PRACTICE
Patricia Bobryk, MHS, PT, MSCS, ATP, Moderator; Robert W. Motl, PhD, Chair - CURRENT TOPICS AND TRENDS IN MS REHAB – PART 4
Patricia Bobryk, MHS, PT, MSCS, ATP, Moderator
RESEARCH (RS)
- DISEASE MANAGEMENT PLATFORMS
- DMX01 » Web: A Pilot Study of Wearables for Bladder Monitoring in People with Multiple Sclerosis
Valerie J. Block, PT, DPTSc - DMX02 » Disease Activity in People with Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder Exposed to Immune Checkpoint Inhibitors: A Multi-Institutional Study
Alexander J. Gill, MD, PhD - DMX03 » Comparison between a Remote Versus Clinic-Based Exercise Intervention for People with Multiple Sclerosis Residing in the Deep South: An Enhancement Non-Inferiority Trial
Salma M. Aly, MD, MPH - DMX04 » Symptom Comparison after Infections Among People with MS
Amber Salter, PhD - DMX05 » Outcomes from a Women’s Health Initiative at the Vanderbilt Multiple Sclerosis Center
Stephanie Taylor, MD - DMX06 » Characterizing Neuro-Qol in Latinx People with Multiple Sclerosis during the COVID-19 Pandemic
Carrie M. Hersh, DO, MSc, FAAN
- DISEASE MODIFYING THERAPIES PLATFORMS
- DMT01 » Effect of Cladribine Tablets on Markers of Disease Progression, Axonal Loss and Oligoclonal Bands in Patients with Relapsing Multiple Sclerosis: Results from MAGNIFY-MS
Nicola De Stefano, MD, PhD - DMT02 » Ocrelizumab Dose Selection for Treatment of Pediatric Relapsing- Remitting Multiple Sclerosis: Pharmacokinetic, Safety, and Efficacy Results from OPERETTA 1
Teri Schreiner, MD, MPH - DMT03 » Safety and Efficacy of Frexalimab in Relapsing Multiple Sclerosis: 48- Week Results from the Phase 2 Open-Label Extension
Yang Mao-Draayer, MD, PhD - DMT04 » Relapse-Associated Worsening and Progression-Independent Relapse Activity in Ozanimod-Treated Participants with Relapsing Multiple Sclerosis from the RADIANCE and DAYBREAK Trials
Jeffrey A. Cohen, MD - DMT05 » Pregnancy and Infant Outcomes in Females Receiving Ocrelizumab for the Treatment of Multiple Sclerosis: Analysis of over 3,000 Pregnancies to Date
Riley Bove, MD - DMT06 » Ocrelizumab Administered Subcutaneously: Results from the Clinical Development Program
Scott D. Newsome, DO, MSCS
- PSYCHOSOCIAL PLATFORMS
- REHABILITATION PLATFORMS
- REH01 » Free-Living Ambulatory Physical Activity and Cognitive Function in Multiple Sclerosis: The Significance of Step Rate Vs. Step Volume
Peixuan Zheng, PhD - REH02 » Project Teaams – Targeted Exercise for African-Americans with Multiple Sclerosis: Preliminary Results
Victoria A. Flores, PhD - REH03 » Intermittent Hypoxia-Induced Neuroplasticity in Persons with Multiple Sclerosis
Milap Sandhu, PT, PhD - REH04 » Relationships between Perceived Fatigue, Ambulation Fatigability, Daily Ambulatory Activity, and Energy Cost of Walking in Multiple Sclerosis: A Pilot Study
Prudence Plummer, PhD, PT - REH05 » Ambulatory Activity between Anti-CD20 Antibody Infusions in People with Multiple Sclerosis
Valerie J. Block, PT, DPTSc
- NEUROIMAGING PLATFORMS
- IMG01 » A 2-Stage Model of Heterogenous Treatment Effects for Brain Atrophy in Multiple Sclerosis Utilizing the MS Paths Research Network
Carrie M. Hersh, DO, MSc, FAAN - IMG02 » Relationship between Serum 24-Hydroxycholesterol and Brain Water Content, Myelin Water Fraction, and T1 Relaxation in Different Stages of MS
Noah Marini, BScN - IMG03 » How to Use Neuro Innovation in Clinical Practice Exploring Radiologically Isolated Syndrome
Mikael Cohen, MD, PhD - IMG04 » Identification of a Distinct Microglial Inflammation Pattern in the Subcortex of MS Patients Using Principal Component Analysis Applied to [11C]PBR28 PET Images
Risavarshni Thevakumaran, BEng, MSc - IMG05 » Performance Evaluation of Neuroquant MS 4.1 for White Matter Lesion Segmentation in Multiple Sclerosis
Saif Baig, MD - IMG06 » Assessing Central Vein Sign Visibility across Various Anisotropic MRI Resolutions for Multiple Sclerosis Diagnosis
Samuel W. Remedios, MSE
- TREATMENT STRATEGIES IN RELAPSING MS: WHAT HAVE WE LEARNED FROM OBSERVATIONAL STUDIES AND BEYOND
Scott D. Newsome, DO, MSCS, FAAN, FANA, Chair- Welcome and Introduction
Scott D. Newsome, DO, MSCS, FAAN, FANA - Birds Eye View on Treatment Strategies
Scott D. Newsome, DO, MSCS, FAAN, FANA - Treatment Strategies in Multiple Sclerosis are Clear as a Crystal
Tirisham Gyang, MD - Treatment Strategies in Multiple Sclerosis are Clear as Mud
Ellen Mowry, MD, MCR, FAAN, FANA - Panel Roundtable-Case Presentations
Panel
SKILLS (SK)
- APPLICATION OF HISTORY & NEUROLOGIC EXAMINATION FOR ACCURATE EXPANDED DISABILITY STATUS SCORE (EDSS) ASSESSMENT
Michael Yeung, MD, FRCPC Jodie Roberts, MD, MSc, FRCPC Co-Chairs- Introduction – Overview of the EDSS – Benefits, Drawbacks, and Historical Significance
Jodie Roberts, MD, MSc, FRCPC - Scoring Kurtzke Functional Systems and Calculating the EDSS
Michael Yeung, MD, FRCPC - Additional Practice Cases
Michael Yeung, MD, FRCPC - Other Common MS Outcome Measures – MSFC & SDMT
Jodie Roberts, MD, MSc, FRCPC
- CONVEYING INFORMATION: HOW YOU SAY IT MATTERS
Angela Lesley Baufeldt, DClinPsy, Chair - OPENING YOUR NURSE PRACTITIONER PRACTICE: TIPS AND CONSIDERATIONS
Aliza Ben-Zacharia, PhD, DNP, ANP-BC, FAAN, Chair- Introduction and Business Plan
Aliza Ben-Zacharia, PhD, DNP, ANP-BC, FAAN - Legal and State Considerations
Sarah Cecil DNP, APRN, FNP-BC, PMHNP-BC, MSCN - Credentialing and Insurance Billing
Aliza Ben-Zacharia, PhD, DNP, ANP-BC, FAAN - Marketing/Social Media
Sarah Cecil DNP, APRN, FNP-BC, PMHNP-BC, MSCN - Final Checklist: Missed Items?
Aliza Ben-Zacharia, PhD, DNP, ANP-BC, FAAN - Conclusion
Sarah Cecil DNP, APRN, FNP-BC, PMHNP-BC, MSCN8:15 am – 9:00 am
- WOMEN IN MULTIPLE SCLEROSIS CARE AND THEIR ALLIES: BUILDING SKILLS FOR THRIVING IN YOUR CAREER
Carrie M. Hersh, DO, MSc, FAAN, Chair- Introductions
- Post-It Ice Breaker Session: Sharing Ideas and Knowledge Gaps
- Professional Growth: Being Intentional About Your Career
Carrie M. Hersh, DO, MSc, FAAN - Emotional Intelligence, Resilience, and Beyond
Mary Alissa Willis, MD, FAAN, FANA - Networking, Negotiating, and Assertiveness Training
Mary Rensel, MD, FAAN - Leveraging Engagement and Allyship for Women Leadership: Successes and Challenges
Amy Sullivan, PsyD, ABPP - Networking/Speed Mentoring/Sharing Ideas
- WHEN FULFILLMENT BECOMES AN INTERNAL FIGHT: MANAGING BURNOUT IN MEDICINE
Amy Sullivan, PsyD, ABPP, Chair- Introduction: Worldview
Amy Sullivan, PsyD, ABPP - Impact of Stress on the Body
Amy Sullivan, PsyD, ABPP - Burnout Stories with Audience Process
Carrie M. Hersh, DO, MSc, FAAN - Combatting Burnout & Time Management for Work-life Integration
Carrie M. Hersh, DO, MSc, FAAN
- MS AND FUNCTIONAL NEUROLOGICAL DISORDER (FND)
John Kramer, PA-C, Chair
SYMPTOMATIC MANAGEMENT (SX)
- BACK TO THE BASICS: AN INTERDISCIPLINARY APPROACH TO MANAGEMENT OF BLADDER AND BOWEL SYMPTOMS
Marie Namey, APRN, MSCN, Chair- Introduction and Focus of Symposia
Marie Namey, APRN, MSCN - The Bladder in MS, Diagnosis and Management
Philip J. Aliotta, MD, MSHA, FACS - Strategies for Assessment and Management of MS Bowel Symptoms
Marie Namey, APRN, MSCN - Optimizing Bladder and Bowel Function from a Rehabilitation Perspective
Cameron Pikula, PT, DPT - Case Studies, Discussion and Questions
Panel
- PATHOPHYSIOLOGY AND MANAGEMENT OF PAIN SYNDROMES IN MULTIPLE SCLEROSIS
Hossein Mousavi, MD, Chair
TECHNOLOGIC ADVANCES (TC)
- JOHN F. KURTZKE MEMORIAL LECTURE (CLICK HERE FOR THE SLIDES)
Click here to watch the video
BEYOND THE SURFACE: CHALLENGING OUR PERCEPTIONS OF MULTIPLE SCLEROSIS
Darin T. Okuda, MD, FAAN, FANA - MRI INTERNATIONAL GUIDELINES IN CLINICAL PRACTICE: CURRENT AND UP-AND-COMING APPROACHES
David K.B. Li, MD; Anthony Traboulsee, MD Co-Chairs- Welcome and Introductions
Anthony Traboulsee, MD - MRI and the Diagnosis and Misdiagnosis of MS
Jiwon Oh, MD, PhD, FRCPC - MS Lesions and Lesion Red Flags
Mike P. Wattjes, MD, PhD - Up-and-coming MRI Biomarkers
Mike P. Wattjes, MD, PhD - MRI in Follow-up for Treatment Effectiveness and Safety
Anthony Traboulsee, MD - Standardized MRI Protocol for MS
David K.B. Li, MD
- DECODING MULTIPLE SCLEROSIS: THE SYNERGY OF AI AND NEUROIMAGING
Robert Zivadinov, MD, PhD, Chair - NEUROIMAGING PLATFORMS
- IMG01 » A 2-Stage Model of Heterogenous Treatment Effects for Brain Atrophy in Multiple Sclerosis Utilizing the MS Paths Research Network
Carrie M. Hersh, DO, MSc, FAAN - IMG02 » Relationship between Serum 24-Hydroxycholesterol and Brain Water Content, Myelin Water Fraction, and T1 Relaxation in Different Stages of MS
Noah Marini, BScN - IMG03 » How to Use Neuro Innovation in Clinical Practice Exploring Radiologically Isolated Syndrome
Mikael Cohen, MD, PhD - IMG04 » Identification of a Distinct Microglial Inflammation Pattern in the Subcortex of MS Patients Using Principal Component Analysis Applied to [11C]PBR28 PET Images
Risavarshni Thevakumaran, BEng, MSc - IMG05 » Performance Evaluation of Neuroquant MS 4.1 for White Matter Lesion Segmentation in Multiple Sclerosis
Saif Baig, MD - IMG06 » Assessing Central Vein Sign Visibility across Various Anisotropic MRI Resolutions for Multiple Sclerosis Diagnosis
Samuel W. Remedios, MSE
- MICROGLIA AND ASTROCYTES IN MS: BIOLOGY, PET IMAGING AND THERAPEUTICS
Wee Yong, PhD, FCAHS, FRSC, Chair - IMAGING PATIENTS WITH MS IN 2024
(Organized by the VA MS Centers of Excellence)
Mitchell Wallin, MD, MPH; Francesca Bagnato, MD, PhD Co-Chairs
WELLNESS (WE)
- COMORBIDITY MANAGEMENT AMONG PEOPLE WITH MULTIPLE SCLEROSIS: THE ROLE OF REGISTERED DIETITIAN NUTRITIONISTS
Tyler J. Titcomb, PhD, RDN, Chair
